PDCD1 and non-small cell lung carcinoma: Although programmed death 1 (PD-1)/Programmed death ligand 1 (PD-L1) blockade shows remarkable therapeutic effects and prolongs patient survival in the clinic, the response rate of unselected NSCLC patients is approximately 20% (2).